AzTrials
AzTrials

Bilateral Refractive AmblyopiaATS7NCT00305955

Bilateral Refractive Amblyopia Treatment Study

An observational study of Bilateral Refractive Amblyopia, run by Jaeb Center for Health Research at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study will be to: Determine the amount of visual acuity improvement with treatment of presumed bilateral refractive amblyopia Determine the time course of visual acuity improvement with treatment Read more about this study

Who is it for?
Ages 3 to 10 years
Conditions the study is for
Bilateral Refractive Amblyopia
What is being tested?
Spectacles
Type of treatment
Medical device
How many people
113 participants
Where
1 siteUnited States
Study dates
Aug 2004to Oct 2006
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 10 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Community sample

Who may be able to join

  • Age 3 to <11 years
  • Able to perform single-surrounded single optotype visual acuity using the ATS HOTV protocol for children 3 to <7 years old and using the E-ETDRS protocol for children 7 to <11 years old
  • Monocular visual acuity in each eye, measured using trial frames or phoropter with best correction derived from cycloplegic refraction, meeting the following criteria:
  • Using E-ETDRS testing for patients age 7 to <11 years: visual acuity 20 to 70 letters (20/40 to 20/400)
  • Using ATS HOTV testing for patients age 3 to <7 years acuity 20/50 to 20/400
  • Refractive error that meets at least one of the following criteria in each eye:
Show all 11Show fewer
  • Spherical equivalent >+4.00 D
  • Astigmatism >2.00 D
  • Investigator believes that the patient's reduced visual acuity is due to bilateral, refractive amblyopia
  • Investigator not planning to prescribe occlusion, patching or any other amblyopia treatment other than spectacles at this time
  • Cycloplegic refraction and ocular examination within 2 months prior to enrollment

Who cannot join

  • Myopia greater than -6.00 D of spherical power in plus cylinder form
  • Ocular cause for decreased acuity in either eye; nystagmus per se will not exclude a patient from the study
  • Refractive correction (spectacles or contact lenses) in past three months and no more than one month of refractive correction ever
  • Prior treatment for amblyopia (other than the refractive correction permitted in previous exclusion criteria)
  • Prior intraocular or refractive surgery
  • Use of contact lenses during the study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Duke University Eye Center

    Durham, North Carolina, 27710

Other trials in United States

About this study

The purpose of this study will be to:

  • Determine the amount of visual acuity improvement with treatment of presumed bilateral refractive amblyopia
  • Determine the time course of visual acuity improvement with treatment
Read the detailed description

There is a paucity of literature on bilateral amblyopia that is due to a substantial amount of refractive error (hypermetropia or astigmatism), and it is limited principally to review articles and case reports. The incidence is not known, but in one study, 4 of 830 (0.5%) children examined at the time of entry into school had bilateral amblyopia. Schoenleber et al performed a retrospective review of office records and identified 184 children with > +4.00 diopters of hypermetropia in both eyes, 12 of whom (6.5%) had bilateral amblyopia of 20/50 or worse. Ten of the 12 children (83%) improved to 20/40 or better in both eyes over a mean follow-up time of 22 months. Werner and Scott reported 6 cases of bilateral hypermetropic amblyopia with a spherical equivalent of at least +5.00 D and an initial visual acuity of 20/40 or worse in both eyes. All 5 patients with follow up improved with glasses alone, and 2 of these 5 had a most recent visual acuity worse than 20/40 in one eye with follow-up less than one year. Cavazos et al identified 218 eyes with hyperopia > +5.00 D or astigmatism >+2.00 D. Of these, 82 (38%) of the dominant eyes had an initial corrected visual acuity less than 20/25. Most improved to > 20/25, but many patients were lost to follow-up. In ongoing studies, bilateral refractive amblyopia is being evaluated in Native Americans.

  1. Patients will be enrolled who have bilateral refractive error with hyperopia >+4.00 D and/or astigmatism >2.00 D and have visual acuity in each eye, measured using best correction derived from cycloplegic refraction, meeting the following criteria:
  • Using E-ETDRS testing for patients age 7 to <11 years: visual acuity 20 to 70 letters (20/40 to 20/400)
  • Using ATS HOTV testing for patients age 3 to <7 years visual acuity 20/50 to 20/400
  1. Enrolled patients will be prescribed spectacles, which will be paid for by the study.
  2. The patient will return for a Spectacle Baseline visit within 30 days, at which time the spectacles will be placed on the patient for the first time and binocular and monocular visual acuities will be measured.
  • Patients whose monocular acuity at the Spectacle Baseline Visit is 20/25 or better in both eyes will end the study
  • Patients whose monocular acuity at the Spectacle Baseline Visit is worse than 20/25 in at least one eye will begin a one-year period of study follow up
  1. Follow-up visits are required at 5±:1 week, 13±:2 weeks, 26±:4 weeks, and 52±:4 weeks.
  • If at any follow-up visit a patient's monocular acuity is 20/25 or better in both eyes, the patient should return for the 52-week visit only and may skip the interim follow-up visits.

Sample size: The study plans to enroll 100 patients. At least 50 patients will be enrolled who have an interocular difference of less than 3 lines by ATS HOTV or less than 15 letters by E-ETDRS at the Spectacle Baseline visit.

Being tested
Spectacles
Keywords
amblyopia, bilateral amblyopia, refractive error
Medical subject headings
Amblyopia, Refractive Errors

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SpectaclesDevice

    optimal spectacle correction

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual acuity of 20/25 or better in both eyes

    Measured: 52 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Mar 2006 (estimated)
  2. Study startAug 2004
  3. Primary completionJul 2006
  4. Study completionOct 2006

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
113 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00305955
Sponsor's protocol ID
NEI-101
Other IDs
2U10EY011751
Acronym
ATS7
Status last verified
Oct 2009
First submitted
20 Mar 2006
Last updated
24 Mar 2010
Results posted
No
Data monitoring committee
No

Publications

  • Wallace DK, Chandler DL, Beck RW, Arnold RW, Bacal DA, Birch EE, Felius J, Frazier M, Holmes JM, Hoover D, Klimek DA, Lorenzana I, Quinn GE, Repka MX, Suh DW, Tamkins S; Pediatric Eye Disease Investigator Group. Treatment of bilateral refractive amblyopia in children three to less than 10 years of age. Am J Ophthalmol. 2007 Oct;144(4):487-96. doi: 10.1016/j.ajo.2007.05.040. Epub 2007 Aug 20.

    PubMed 17707330

Questions about this trial

What is this clinical trial studying?

An observational study of Bilateral Refractive Amblyopia, run by Jaeb Center for Health Research at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Mar 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual acuity of 20/25 or better in both eyes (time frame: 52 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00305955, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2010.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in